Uterine abnormalities in non menopausal women received tamoxifen for breast cancer adjuvant therapy;Anomalies utérines chez la femme non ménopausée sous tamoxifène en traitement adjuvant du cancer du sein

Gynecologie Obstetrique et Fertilite

Volumn 35, Issue 12, 2007, Pages 1215-1219

  d'Arailh, A S ^a   Michy, T ^a   Pioud, R ^a   Dravet, F ^a   Classe, J M ^a  

^a CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

Non menopausal women; Polyps; Surveillance; Tamoxifen; Ultrasound

Indexed keywords

TAMOXIFEN;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; ENDOMETRIAL DISEASE; ENDOMETRIUM HYPERPLASIA; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; HYPERPLASIA; HYSTEROSCOPY; MAJOR CLINICAL STUDY; MENOPAUSE; UTERUS BLEEDING; UTERUS MALFORMATION;

EID: 37049013682     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/j.gyobfe.2007.10.006     Document Type: Article

References (29)

1. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351 9114 (1998) 1451-1467
2. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 18 (1998) 1371-1388
3. Powles T., Eeles R., Ashley S., Easton D., Chang J., Dowsett M., et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352 9122 (1998) 98-101
4. Baum M., Budzar A.U., Cuzick J., Forbes J., Houghton J.H., Klijn J.G., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 9324 (2002) 2131-2139
5. Fisher B., Land S., Mamounas E., Dignam J., Fisher E.R., and Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol 28 4 (2001) 400-418
6. Ascher S.M., Imaoka I., and Lage J.M. Tamoxifen-induced uterine abnormalities: the role of imaging. Radiology 214 1 (2000) 29-38
7. Neven P., De Muylder X., and Van Belle Y. Tamoxifen-induced endometrial polyp. N Engl J Med 336 19 (1997) 1389 author reply 1389-90
8. Fung M.F., Reid A., Faught W., Le T., Chenier C., Verma S., et al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol Oncol 91 1 (2003) 154-159
9. De Muylder X., Neven P., De Somer M., Van Belle Y., Vanderick G., and De Muylder E. Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynaecol Obstet 36 2 (1991) 127-130
10. Berezowsky J., Chalvardjian A., and Murray D. Iatrogenic endometrial megapolyps in women with breast carcinoma. Obstet Gynecol 84 4 Pt 2 (1994) 727-730
11. Varras M., Polyzos D., and Akrivis C. Effects of tamoxifen on the human female genital tract: review of the literature. Eur J Gynaecol Oncol 24 3-4 (2003) 258-268
12. Assikis V.J., and Jordan V.C. Gynecologic effects of tamoxifen and the association with endometrial carcinoma. Int J Gynaecol Obstet 49 3 (1995) 241-257
13. Folk J.J., Mazur M.T., Eddy G.L., and Musa A.G. Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case. Gynecol Oncol 58 1 (1995) 133-135
14. Biron-Shental T., Tepper R., Fishman A., Shapira J., and Cohen I. Recurrent endometrial polyps in postmenopausal breast cancer patients on tamoxifen. Gynecol Oncol 90 2 (2003) 382-386
15. Cohen I., Bernheim J., Azaria R., Tepper R., Sharony R., and Beyth Y. Malignant endometrial polyps in postmenopausal breast cancer tamoxifen-treated patients. Gynecol Oncol 75 1 (1999) 136-141
16. Deligdisch L., Kalir T., Cohen C.J., de Latour M., Le Bouedec G., and Penault-Llorca F. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol 78 2 (2000) 181-186
17. Mbatsogo B.A., Le Bouedec G., Michy T., Bourdel N., Fouilloux G., and Dauplat J. [Endometrial cancers arising in polyps associated with tamoxifen use]. Gynecol Obstet Fertil 33 12 (2005) 975-979
18. Tate S.Y.K., and Sehiya S. Endometrial cancer within tamoxifen-related polyps in patients with breast cancer. Acta Obstet Gynecol Scand 83 (2004) 769-770
19. Gerber B., Krause A., Muller H., Reimer T., Kulz T., Makovitzky J., et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol 18 20 (2000) 3464-3470
20. Barakat R.R., Gilewski T.A., Almadrones L., Saigo P.E., Venkatraman E., Hudis C., et al. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. J Clin Oncol 18 20 (2000) 3459-3463
21. Carter JR TL. The role of transvaginal sonography in gynecologic oncology. In: Studd J, ed. Progress in obstetrics and gynecology. Vol 10, London: Churchill Livingstone. 1993: 351-57.
22. Berliere M., Galant C., Gillerot S., Charles A., and Donnez J. [Endometrial evaluation prior to tamoxifen: preliminary results of a prospective study]. Bull Cancer 85 8 (1998) 721-724
23. ACOG practice bulletin. Selective estrogen receptor modulators. Number 39, October 2002 (replaces Committee Opinion Number 224, October 1999). Int J Gynaecol Obstet 2002; 79(3):289-98.
24. Machado F., Rodriguez J.R., Leon J.P., Rodriguez J.R., Parrilla J.J., and Abad L. Tamoxifen and endometrial cancer. Is screening necessary? A review of the literature. Eur J Gynaecol Oncol 26 3 (2005) 257-265
25. Hulka C.A., and Hall D.A. Endometrial abnormalities associated with tamoxifen therapy for breast cancer: sonographic and pathologic correlation. AJR Am J Roentgenol 160 4 (1993) 809-812
26. Randolph Jr. J.F., Ying Y.K., Maier D.B., Schmidt C.L., and Riddick D.H. Comparison of real-time ultrasonography, hysterosalpingography, and laparoscopy/hysteroscopy in the evaluation of uterine abnormalities and tubal patency. Fertil Steril 46 5 (1986) 828-832
27. Tepper R., Beyth Y., Altaras M.M., Zalel Y., Shapira J., Cordoba M., et al. Value of sonohysterography in asymptomatic postmenopausal tamoxifen-treated patients. Gynecol Oncol 64 3 (1997) 386-391
28. Alcazar J.L., Castillo G., Minguez J.A., and Galan M.J. Endometrial blood flow mapping using transvaginal power Doppler sonography in women with postmenopausal bleeding and thickened endometrium. Ultrasound Obstet Gynecol 21 6 (2003) 583-588
29. Kontostolis E., Stefanidis K., Navrozoglou I., Mouzakioti E., Paschopoulos M., and Lolis D. The effects of tamoxifen on the endometrium, blood flow of the uterine arteries and serum lipoprotein (a) levels in postmenopausal women. Gynecol Endocrinol 12 3 (1998) 185-189